Key result
Iopromide matches iodixanol with similarly low CIN rates in patients undergoing coronary procedures.
Why the study?
The comparative nephrotoxicity of low-osmolar iopromide versus iso-osmolar iodixanol in patients with moderate renal dysfunction undergoing coronary angiography or PCI was unclear.
Does iopromide compared to iodixanol reduce contrast-induced nephropathy in renally impaired patients undergoing cardiac catheterisation?
RCT (n=562)
Double-blind
randomised
Yes
Does iopromide compared to iodixanol reduce contrast-induced nephropathy in renally impaired patients undergoing cardiac catheterisation?
Answers are grounded in this paper and cite their sources.
In patients with moderate renal dysfunction undergoing cardiac catheterization with rigorous hydration, there is no significant difference in nephrotoxicity between iopromide and iodixanol.
AIMS: This multi-centre, randomised, double-blind study compared the nephrotoxicity of low-osmolar, low-viscous iopromide and iso-osmolar, high-viscous iodixanol in Chinese patients with moderate renal dysfunction, after coronary angiography or percutaneous coronary intervention (PCI). METHODS AND RESULTS: The primary endpoint was contrast-induced nephropathy (CIN) on day 3, defined as a post-dose increase in serum creatinine (SCr) of ≥50% from baseline. All patients were rigorously hydrated from six hours before intervention. In 562 evaluable patients (of 592 recruited), the contrast volume, presence of diabetes mellitus, mean baseline SCr and estimated glomerular filtration rate (eGFR) were comparable between the iopromide- and iodixanol-treated groups. SCr increases of ≥50% occurred in 1/278 (0.4%) of patients after iopromide and 1/284 (0.3%) after iodixanol. Incidences in the secondary endpoints were the following: SCr increases of ≥0.5 mg/dL, 1.4% and 0.7%, respectively; SCr increases of ≥25%, 5.4% and 2.8%; eGFR decreases of ≥25%, 3.6% and 2.5%. Only one patient showed renal failure, one week after dosing with iodixanol. All differences were statistically insignificant, in the overall collective group and in the subgroup with diabetes (n=170). CONCLUSIONS: With rigorous hydration, the CIN incidence was very low in patients with moderate renal dysfunction who underwent coronary angiography or PCI. No difference in nephrotoxicity was found between iopromide and iodixanol.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2012) conducted an RCT in Moderate renal dysfunction (n=562). Iopromide vs. Iodixanol was evaluated on Contrast-induced nephropathy (CIN) on day 3, defined as a post-dose increase in serum creatinine (SCr) of ≥50% from baseline (p=statistically insignificant). Iopromide and iodixanol resulted in similarly low rates of contrast-induced nephropathy in patients with moderate renal dysfunction undergoing coronary angiography or PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: